

Xiang Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10221236/publications.pdf>

Version: 2024-02-01

9
papers

188
citations

1478505
6
h-index

1474206
9
g-index

9
all docs

9
docs citations

9
times ranked

229
citing authors

#	ARTICLE	IF	CITATIONS
1	Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111876.	5.5	98
2	Effects of gender on ketamine-induced conditioned place preference and urine metabonomics. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 77, 263-274.	2.7	18
3	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3K γ . <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 4537-4543.	3.0	16
4	Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1138-1142.	2.2	14
5	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold. <i>European Journal of Medicinal Chemistry</i> , 2020, 199, 112339.	5.5	14
6	A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation. <i>Bioorganic Chemistry</i> , 2020, 97, 103666.	4.1	10
7	Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation. <i>Bioorganic Chemistry</i> , 2021, 109, 104714.	4.1	8
8	Discovery of novel steroidal-chalcone hybrids with potent and selective activity against triple-negative breast cancer. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115763.	3.0	7
9	Synthesis and structure-activity relationships of pirfenidone derivatives as anti-fibrosis agents <i>in vitro</i> . <i>RSC Medicinal Chemistry</i> , 2022, 13, 610-621.	3.9	3